Catherine Hall, VP Product Strategy at endpoint Clinical and Michael MacNeir, VP of Commercial Operations North America at Marken. present a Case Study on Direct-to-Patient Logistics discussing how the evolution of direct-to-patient trials has an impact on the overall clinical eco-system. and speculates on the future at Direct-to-Patient and Virtual, Decentralized, and Hyper Clinical Trials. Learning from the evolution of technology and trial design to address the barriers of Direct to Patient and how COVID-19 is reshaping the future of decentralized trials.
Cat Hall started her career as an academic scientist in Molecular and Cellular Biology before finishing her MBA and transitioning into Pharmaceutical Supply Chain Management. During her career, she developed notable expertise not only in clinical supplies but also in training development, process improvement, managing partnerships, and the design and implementation of technologies such as Interactive Response Technology (IRT). She is well-known for focusing on bridging the GMP/GCP gap by bringing supply chain customer service through the last mile to patients. Cat joined endpoint in 2019 as VP of Product Strategy to help continue to bring the customer voice forward into shaping the future of IRT.
Michael MacNeir, VP of Commercial Operations North America at Marken
Michael MacNeir is a leader in Marken’s Commercial Operations team. Michael currently has over 11 years of experience in the Pharmaceutical and Life Science Industries with strong experience in decentralized models and supply chain. His peers and clients find him to be focused on individual client’s needs and project-focused with innovative ideas and solutions to overcome challenges within the clinical supply chain.
He came to Marken as Director of Commercial Operations and quickly became the Subject Matter Expert for Marken Direct-to-Patient services globally. He currently manages the US sales team.
Call us from within the United States:
Calling from outside the United States?